GO BEYOND RNA — Epitranscriptomics & ncRNA Services Toll Free: 1-888-416-6343  ·  Fax: 240-238-9860
Arraystar - Go Beyond RNA
Small RNA Modification Sequencing

m3C-IP-Seq — Single-Nucleotide tRNA m³C Modification Seq

m3C-IP-Seq profiles N3-methylcytidine on tRNA with an m³C-specific antibody. Immunoprecipitation concentrates m³C-bearing fragments, and reverse-transcription misincorporation at the modified cytidine is then resolved to a single base.

m³C-antibody IP enrichment plus single-base read-out · per-site stoichiometry

Overview

Single-base m³C calling on tRNA

N3-methylcytidine sits on the Watson–Crick face, where it changes how cytidine pairs and how the anticodon loop behaves. Because it is present at a limited set of tRNA positions, mapping it means separating a small number of modified cytosines from the unmodified background.

Arraystar Single-Nucleotide tRNA m³C Modification Seq(m3C-IP-Seq) is an end-to-end sample-to-data service for tRNA, running from RNA sample QC and tRNA treatment through library construction, sequencing and bioinformatics. Sites are localized within mature tRNA transcripts with relative coordinates, gene attribution, anticodon and isotype, and structural-domain context.

What is tRNA m3C-IP-Seq?

m3C-IP-Seq is an antibody-based sequencing service in which an m³C-specific antibody immunoprecipitates m³C-containing fragments, and reverse-transcription misincorporation at the modified cytidine is called at single-base resolution, giving sensitive, quantitative m³C profiling across tRNA.

Service at a Glance

Standard tRNA m³C project — custom designs and add-on analyses available on request

Service NamePrice
Single-Nucleotide tRNA m³C Modification Seq(m3C-IP-Seq)

Benefits

What m3C-IP-Seq adds to tRNA methylome work

Enrichment then resolution

The antibody IP step concentrates m³C-bearing fragments, and the reverse-transcription read-out then fixes the modified nucleotide to a single base.

Quantitative fractions

Misincorporation signal at each position yields the m³C fraction, which can be compared between samples.

Antibody-based enrichment

An m³C-specific antibody concentrates the modified fragments, so low-abundance m³C positions are pulled out of the unmodified background.

Annotated within mature tRNA

Sites carry relative coordinates, host tRNA gene, anticodon, isotype and structural-domain assignment.

Complementary to chemical cleavage

The workflow gives an independent route to tRNA m³C alongside cleavage-based sequencing.

One project, end to end

RNA QC, tRNA processing, library construction, sequencing and analysis are handled together.

Background

Reading m³C inside tRNA

m³C at the anticodon loop is a conserved tRNA modification, and its position determines how it affects structure and decoding. Distinguishing the modified cytidines from the many unmodified ones is the central analytical problem, particularly because tRNA is short and heavily folded.

An m³C-specific antibody immunoprecipitates m³C-containing fragments, and reverse-transcription misincorporation at the modified cytidine is resolved to a single base, giving sensitive m³C mapping inside mature tRNA transcripts. A matched AlkB demethylase (Dm) control removes m³C from one arm of the IP eluate, so true m³C sites show misincorporation only in the non-Dm arm and read back as unmodified C after demethylation. Arraystar runs this end to end and reports each site with its tRNA context (1).

tRNA m³C
Figure 1. m3C-IP-Seq detection scheme. An m³C-antibody IP enriches m³C-bearing fragments; the IP eluate is split into an AlkB-demethylated arm (Dm) and a non-Dm arm. Reverse transcription records m³C as misincorporation only in non-Dm, so high-confidence sites lose that signal after Dm.

tRNA m3C-IP-Seq Workflow

From total RNA to base-resolution m³C calls

The sample moves through RNA QC and tRNA treatment, m³C-directed immunoprecipitation, a split of the IP eluate into an AlkB-demethylated arm (Dm) and an untreated arm (non-Dm), library construction and sequencing, and finally tRNA-aware calling. Reverse transcription records m³C as misincorporation in the non-Dm arm while the Dm arm reads as unmodified C; only sites that lose their signal after Dm are reported as high-confidence per-site m³C values.

tRNA m3C-IP-Seq Workflow
Figure 2. Single-Nucleotide tRNA m³C Modification Seq workflow.

Bioinformatics & Deliverables

Bioinformatics for m3C-IP-Seq

Reads are mapped to a curated tRNA reference, m3C-IP-Seq misincorporation signatures are called in the non-Dm arm, sites that persist in the AlkB-demethylated (Dm) arm are removed, and per-position stoichiometry is reported with motif, differential, enrichment and genome-browser outputs. The Dm versus non-Dm comparison turns raw misincorporation into high-confidence single-base calls.

Standard Deliverables

Research Applications

Research directions for tRNA m³C

Anticodon-loop function

Places m³C inside anticodon context to test its effect on decoding.

tRNA methylome comparison

Contrasts m³C occupancy between conditions or between tRNA families.

Writer and eraser studies

Tests how methyltransferase perturbations change m³C at specific sites.

Isotype-resolved analysis

Groups calls by isotype and isoacceptor for family-level comparisons.

Disease-oriented screening

Identifies differentially methylated tRNA positions between groups.

Sample Requirements

Sample handling and submission for tRNA m³C

Sample Storage

  • For cells/tissue: use TRIzol or an RNA-stabilizing reagent, quick-freeze in liquid nitrogen, and keep at –80 °C.
  • For RNA: dissolve in ethanol or RNase-free water, store at –80 °C, and limit freeze–thaw cycles.

Shipping Instructions

  • Transfer each sample into a 1.5 mL nuclease-free tube.
  • Close the tube securely with parafilm or a cap lock to preserve integrity.
  • Send on dry ice with sufficient insulation to sustain the required temperature.
Sample TypeNotes
Whole bloodUse EDTA tubes only; heparin is not compatible with subsequent analytical procedures.
Cultured cellsCell pellets are preferred to ensure high-quality material for processing.
TissueProvide fresh or frozen specimens and avoid necrotic material.
Total RNAMaintain an OD 260/280 ratio ≥ 1.8 and RIN ≥ 7 with no visible degradation. Submit at least 200 µg total RNA.

Submit at least 200 µg total RNA per sample; this assay consumes more input than the antibody-free chemical workflows. Questions: support@arraystar.com

FAQ

Questions we are asked about tRNA m3C-IP-Seq

Why combine antibody enrichment with a reverse-transcription read-out?
Immunoprecipitation concentrates the small fraction of tRNA fragments that carry m³C, and the reverse-transcription signature then reports the modified nucleotide itself. Together they give sensitivity to rare sites while keeping base-level resolution, which neither step would deliver on its own.
Does the assay use an antibody?
Yes. An m³C-specific antibody carries out the immunoprecipitation step, and that enrichment separates m³C-bearing fragments from the unmodified background. The single-base call comes from misincorporation during reverse transcription, so the reported position is read from the sequencing data rather than inferred from the antibody alone.
Which tRNA features are annotated?
Each site is reported with relative coordinates inside the mature tRNA transcript, host tRNA gene attribution, anticodon and isotype, and structural-domain localisation, so a position can be interpreted within its own tRNA rather than as a coordinate on a generic reference.
How does the Dm (AlkB) control support high-confidence calls?
One arm of the IP eluate is demethylated with AlkB (Dm) and the other is left untreated (non-Dm). True m³C sites show reverse-transcription misincorporation in non-Dm and lose that signal after demethylation; sites that remain in both arms are treated as background and removed before reporting.
How does m³C-IP-Seq relate to cleavage-based m³C methods?
The two approaches reach the same modification by different chemistry. Running them in parallel provides independent confirmation of a site and lets cleavage-based and enrichment-based evidence be compared for the same tRNA, which is useful when a position is being reported for the first time.
Can differential m³C be tested between groups?
Yes. Per-position stoichiometry is reported for every sample, and differential analysis with fold change and significance is part of the standard pipeline, so m³C shifts between conditions can be called directly at the level of individual tRNA positions across a time course or treatment series.

Selected Publications

Key references for tRNA m³C

  1. Gao Y, Hou J, Wei S, et al. Transcriptome-wide mapping of N3-methylcytidine modification at single-base resolution. Nucleic Acids Research, 2025. PMID: 40071931

Map m³C Inside Your tRNA Samples

Arraystar tRNA m3C-IP-Seq combines targeted enrichment with a base-resolution read-out — send your sample set and we will return annotated, quantitative m³C calls.